Bevilacqua M, Bettica P, Milani M, Vago T, Rogolino A, Righini V, Santoli E, Norbiato G
Department of Endocrinology, Ospedale L. Sacco, Milan, Italy.
Am J Cardiol. 1997 Jan 1;79(1):84-7. doi: 10.1016/s0002-9149(96)00684-4.
This randomized, double-blind, placebo-controlled study shows that 20-week fluvastatin treatment induces beneficial changes in the lipid panel and a shift in the fibrinolytic pathway toward activation through a decrease in tissue plasminogen activator antigen. Fluvastatin treatment causes no variation in lipoprotein(a) circulating levels.
这项随机、双盲、安慰剂对照研究表明，氟伐他汀20周治疗可诱导血脂谱发生有益变化，并通过降低组织纤溶酶原激活物抗原使纤维蛋白溶解途径向激活方向转变。氟伐他汀治疗不会引起循环中脂蛋白(a)水平的变化。
